| Autor: |
Darren W-T. Lim, Luigi Manenti, Romain Séchaud, Jennifer Mataraza, Hongzi Liang, Yao Yao, Sebastian Szpakowski, Juan Gonzalez-Maffe, Steven McCune, Joël Guigay, Ammar Sukari, Alexander I. Spira, Zujun Li, Pei-Jen Lou, Victor H.F. Lee, Suebpong Tanasanvimon, Brigette B.Y. Ma, Somvilai Chakrabandhu, Po Chung Chan, Chia-Jui Yen, Li Zhang, Arunee Dechaphunkul, Roger K-C Ngan, Shau-Hsuan Li, Hung-Ming Wang, Caroline Even |
| Rok vydání: |
2023 |
| DOI: |
10.1158/1078-0432.c.6531318 |
| Popis: |
Purpose:No standard treatment exists for platinum-refractory, recurrent/metastatic nasopharyngeal cancer (NPC). This phase II study (NCT02605967) evaluated progression-free survival (PFS) of spartalizumab, an antiprogrammed cell death protein-1 (PD-1) monoclonal antibody, versus chemotherapy, in NPC.Patients and Methods:Patients with nonkeratinizing recurrent/metastatic NPC who progressed on/after platinum-based chemotherapy were enrolled. Spartalizumab was dosed 400 mg once every 4 weeks, and chemotherapy was received per investigator's choice.Results:Patients were randomized to receive either spartalizumab (82 patients) or chemotherapy (40 patients). The most common spartalizumab treatment-related adverse events were fatigue (10.3%) and pruritus (9.3%). Median PFS in the spartalizumab arm was 1.9 months versus 6.6 months in the chemotherapy arm (P = 0.915). The overall response rate in the spartalizumab arm was 17.1% versus 35.0% in the chemotherapy arm. Median duration of response was 10.2 versus 5.7 months in the spartalizumab versus chemotherapy arms, respectively. Median overall survival was 25.2 and 15.5 months in the spartalizumab and chemotherapy arms, respectively. Tumor RNA sequencing showed a correlation between response to spartalizumab and IFNγ, LAG-3, and TIM-3 gene expression.Conclusions:Spartalizumab demonstrated a safety profile consistent with other anti–PD-1 antibodies. The primary endpoint of median PFS was not met; however, median overall survival and median duration of response were longer with spartalizumab compared with chemotherapy. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
